Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi:10.5114/pg.2018.81072.
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of largebowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central cancer treatment group and the Mayo clinic. J Clin Oncol. 1989;7(10):1447–1456. doi:10.1200/JCO.1989.7.10.1447.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected Colon carcinoma. N Engl J Med. 1990;322(6):352–358. doi:10.1056/NEJM199002083220602.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III Colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321–326. doi:10.7326/0003-4819-122-5-199503010-00001.
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for Colon cancer. N Engl J Med. 2004;350(23):2343–2351. doi:10.1056/NEJMoa032709.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III Colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733–3740. doi:10.1200/JCO.2015.60.9107.
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III Colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–2204. doi:10.1200/JCO.2006.08.2974.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer, version 2. 2022. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed November 2022.
   Google Scholar
• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Rectal Cancer, version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed November 2022.
   Google Scholar
• Osumi H, Shinozaki E, Suenaga M, et al. Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer. PLoS One. 2017;12(5):e0176745. doi:10.1371/journal.pone.0176745.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected Colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–1097. doi:10.1056/NEJMoa010957.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Carpenter WR, Stürmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III Colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30(21):2624–2634. doi:10.1200/JCO.2011.41.1140.
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III Colon cancer: findings from the ACCENT database. J Clin Oncol. 2013;31(20):2600–2606. doi:10.1200/JCO.2013.49.6638.
   PubMed Web of Science ®Google Scholar
• Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III Colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26(4):715–724. doi:10.1093/annonc/mdv003.
   PubMed Web of Science ®Google Scholar
• Hoeben KW, van Steenbergen LN, van de Wouw AJ, et al. Treatment and complications in elderly stage III Colon cancer patients in The Netherlands. Ann Oncol. 2013;24(4):974–979. doi:10.1093/annonc/mds576.
   PubMed Web of Science ®Google Scholar
• Lund CM, Nielsen D, Dehlendorff C, et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1(5):e000087. doi:10.1136/esmoopen-2016-000087.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with Colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516. doi:10.1093/annonc/mds236.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual. 8th ed. NewYork (NY): Springer, 2017.
   Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12):1935–1937. doi:10.1200/JCO.1990.8.12.1935.
   PubMed Web of Science ®Google Scholar
• Hashiguchi Y, Muro K, Saito Y, et al. Japanese society for cancer of the Colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. doi:10.1007/s10147-019-01485-z.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer, version 2.2012. 2012.
   Google Scholar
• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Rectal Cancer, version 2.2012. 2012.
   Google Scholar
• Yamano T, Yamauchi S, Kimura K, et al. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer. 2017;81:90–101. doi:10.1016/j.ejca.2017.05.024.
   PubMed Web of Science ®Google Scholar
• Kawamura H, Morishima T, Sato A, et al. Effect of adjuvant chemotherapy on survival benefit in stage III Colon cancer patients stratified by age: a japanese realworld cohort study. BMC Cancer. 2020;20(1):19. doi:10.1186/s12885-019-6508-1.
   PubMed Web of Science ®Google Scholar
• Doat S, Thiébaut A, Samson S, et al. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer. 2014;50(7):1276–1283. doi:10.1016/j.ejca.2013.12.026.
   PubMed Web of Science ®Google Scholar
• Mahoney T, Kuo YH, Topilow A, et al. Stage III Colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000;135(2):182–185. doi:10.1001/archsurg.135.2.182.
   PubMedGoogle Scholar
• Ko JJ, Kennecke HF, Lim HJ, et al. Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III Colon cancer. Clin Colorectal Cancer. 2016;15(2):179–185. doi:10.1016/j.clcc.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Boyle JM, Kuryba A, Cowling TE, et al. Determinants of variation in the use of adjuvant chemotherapy for stage III Colon cancer in England. Clin Oncol (R Coll Radiol). 2020;32(5):e135-144–e144. doi:10.1016/j.clon.2019.12.008.
   Web of Science ®Google Scholar
• Lemmens VEPP, van Halteren AH, Janssen-Heijnen ML, et al. Adjuvant treatment for elderly patients with stage III Colon cancer in the Southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005;16(5):767–772. doi:10.1093/annonc/mdi159.
   PubMed Web of Science ®Google Scholar
• Paterson HM, Mander BJ, Muir P, et al. Deprivation and access to treatment for colorectal cancer in southeast Scotland 2003–2009. Colorectal Dis. 2014;16(2):O51–57.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Argilés G, Oki E, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis treatment and follow-up of patients with localised Colon cancer. Ann Oncol. 2021;32(12):1496–1510. doi:10.1016/j.annonc.2021.08.1752.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, van der Geest LGM, Giltay EJ, et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol. 2013;4(3):218–226. doi:10.1016/j.jgo.2013.04.001.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cress RD, Stewart SL, et al. Mediating effect of postsurgical chemotherapy on presence of dementia and survival among patients 65 and older with stage III Colon cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1558–1563. doi:10.1158/1055-9965.EPI-17-0277.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Bouché O, Etienne PL, et al. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III Colon cancer from the PRODIGE 34-FFCD randomized trial. Dig Liver Dis. 2022;55(4):541–548.
   PubMedGoogle Scholar
• Antonio M, Saldaña J, Carmona-Bayonas A, et al. Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making? Oncologist. 2017;22(8):934–943. doi:10.1634/theoncologist.2016-0462.
   PubMed Web of Science ®Google Scholar
• Beukers K, Bessems SAM, van de Wouw AJ, et al. Associations between the geriatric-8 and 4-meter gait speed test and subsequent delivery of adjuvant chemotherapy in older patients with Colon cancer. J Geriatr Oncol. 2021;12(8):1166–1172. doi:10.1016/j.jgo.2021.05.004.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Nozawa H, Emoto S, et al. Adjuvant capecitabine and oxaliplatin for elderly patients with colorectal cancer. Oncology. 2022;100(11):576–582. doi:10.1159/000527012.
   PubMed Web of Science ®Google Scholar
• van Erning FN, Razenberg LGEM, Lemmens VEPP, et al. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III Colon cancer patients. Eur J Cancer. 2016;61:1–10. doi:10.1016/j.ejca.2016.03.074.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Osterman E. Adjuvant chemotherapy in elderly colorectal cancer patients. Cancers (Basel). 2020;12(8):2289. doi:10.3390/cancers12082289.
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26(13):2118–2123. doi:10.1200/JCO.2007.15.2090.
   PubMed Web of Science ®Google Scholar
• Kotaka M, Yamanaka T, Yoshino T, et al. Safety data from the phase III japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III Colon cancer. ESMO Open. 2018;3(3):e000354. doi:10.1136/esmoopen-2018-000354.
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Souglakos J, Georgoulias V. Prognostic and predictive significance of MSI in stages II/III Colon cancer. World J Gastroenterol. 2014;20(22):6809–6814. doi:10.3748/wjg.v20.i22.6809.
   PubMed Web of Science ®Google Scholar
• Cohen R, Taieb J, Fiskum J, et al. Microsatellite instability in patients with stage III Colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol. 2021;39(6):642–651. doi:10.1200/JCO.20.01600.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in Colon cancer. J Clin Oncol. 2010;28(20):3219–3226. doi:10.1200/JCO.2009.27.1825.
   PubMed Web of Science ®Google Scholar